1.
Product Overview
1.1.
Market Definition
1.2.
Scope of the Market
1.2.1.
Markets Covered
1.2.2.
Years Considered for Study
1.2.3.
Key Market Segmentations
2.
Research Methodology
2.1.
Objective of the Study
2.2.
Baseline Methodology
2.3.
Key Industry Partners
2.4.
Major Association and Secondary Sources
2.5.
Forecasting Methodology
2.6.
Data Triangulation & Validation
2.7. Assumptions
and Limitations
3.
Executive Summary
3.1.
Overview of the Market
3.2.
Overview of Key Market Segmentations
3.3.
Overview of Key Market Players
3.4.
Overview of Key Regions/Countries
3.5.
Overview of Market Drivers, Challenges, and Trends
4.
Voice of Customer
5. Global
CAR-T Cell Therapy Market Outlook
5.1.
Market Size & Forecast
5.1.1.
By Value
5.2.
Market Share & Forecast
5.2.1.
By Product Type (Yescarta (Axicabtagene Ciloleucel),
Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi
(Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others)
5.2.2.
By Tumor Type (Hematological Malignancies, Solid
Tumors)
5.2.3.
By Indication (Diffused Large B-Cell Lymphoma (DLBCL),
Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell
Lymphoma (MCL), Others)
5.2.4.
By Targeted Antigen (CD 19, BCMA (B-Cell Maturation
Antigen), Others)
5.2.5.
By End User (Hospitals, Specialty Clinics, Ambulatory
Surgical Centers, Others)
5.2.6.
By Treatment Type (Single Treatment, Combination
Treatment)
5.2.7.
By Company (2023)
5.2.8.
By Region
5.3.
Market Map
6. North
America CAR-T Cell Therapy Market Outlook
6.1.
Market Size & Forecast
6.1.1.
By Value
6.2.
Market Share & Forecast
6.2.1. By
Product Type
6.2.2. By
Tumor Type
6.2.3. By
Indication
6.2.4. By
Targeted Antigen
6.2.5.
By End User
6.2.6.
By Treatment Type
6.2.7.
By Country
6.3.
North America: Country Analysis
6.3.1.
United States CAR-T Cell Therapy Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Product Type
6.3.1.2.2.
By Tumor Type
6.3.1.2.3.
By Indication
6.3.1.2.4.
By Targeted Antigen
6.3.1.2.5.
By End User
6.3.1.2.6.
By Treatment Type
6.3.2.
Mexico CAR-T Cell Therapy Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Product Type
6.3.2.2.2.
By Tumor Type
6.3.2.2.3.
By Indication
6.3.2.2.4.
By Targeted Antigen
6.3.2.2.5.
By End User
6.3.2.2.6.
By Treatment Type
6.3.3.
Canada CAR-T Cell Therapy Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Product Type
6.3.3.2.2.
By Tumor Type
6.3.3.2.3.
By Indication
6.3.3.2.4.
By Targeted Antigen
6.3.3.2.5.
By End User
6.3.3.2.6.
By Treatment Type
7. Europe
CAR-T Cell Therapy Market Outlook
7.1.
Market Size & Forecast
7.1.1.
By Value
7.2.
Market Share & Forecast
7.2.1. By
Product Type
7.2.2.
By Tumor Type
7.2.3.
By Indication
7.2.4.
By Targeted Antigen
7.2.5.
By End User
7.2.6.
By Treatment Type
7.2.7.
By Country
7.3.
Europe: Country Analysis
7.3.1.
France CAR-T Cell Therapy Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Product Type
7.3.1.2.2.
By Tumor Type
7.3.1.2.3.
By Indication
7.3.1.2.4.
By Targeted Antigen
7.3.1.2.5.
By End User
7.3.1.2.6.
By Treatment Type
7.3.2.
Germany CAR-T Cell Therapy Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Product Type
7.3.2.2.2.
By Tumor Type
7.3.2.2.3.
By Indication
7.3.2.2.4.
By Targeted Antigen
7.3.2.2.5.
By End User
7.3.2.2.6.
By Treatment Type
7.3.3.
United Kingdom CAR-T Cell Therapy Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Product Type
7.3.3.2.2.
By Tumor Type
7.3.3.2.3.
By Indication
7.3.3.2.4.
By Targeted Antigen
7.3.3.2.5.
By End User
7.3.3.2.6.
By Treatment Type
7.3.4.
Italy CAR-T Cell Therapy Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Product Type
7.3.4.2.2.
By Tumor Type
7.3.4.2.3.
By Indication
7.3.4.2.4.
By Targeted Antigen
7.3.4.2.5.
By End User
7.3.4.2.6.
By Treatment Type
7.3.5.
Spain CAR-T Cell Therapy Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Product Type
7.3.5.2.2.
By Tumor Type
7.3.5.2.3.
By Indication
7.3.5.2.4.
By Targeted Antigen
7.3.5.2.5.
By End User
7.3.5.2.6.
By Treatment Type
8. Asia-Pacific
CAR-T Cell Therapy Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1. By
Product Type
8.2.2. By
Tumor Type
8.2.3.
By Indication
8.2.4.
By Targeted Antigen
8.2.5.
By End User
8.2.6.
By Treatment Type
8.2.7.
By Country
8.3.
Asia-Pacific: Country Analysis
8.3.1.
China CAR-T Cell Therapy Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Product Type
8.3.1.2.2.
By Tumor Type
8.3.1.2.3.
By Indication
8.3.1.2.4.
By Targeted Antigen
8.3.1.2.5.
By End User
8.3.1.2.6.
By Treatment Type
8.3.2.
India CAR-T Cell Therapy Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Product Type
8.3.2.2.2.
By Tumor Type
8.3.2.2.3.
By Indication
8.3.2.2.4.
By Targeted Antigen
8.3.2.2.5.
By End User
8.3.2.2.6.
By Treatment Type
8.3.3.
South Korea CAR-T Cell Therapy Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Product Type
8.3.3.2.2.
By Tumor Type
8.3.3.2.3.
By Indication
8.3.3.2.4.
By Targeted Antigen
8.3.3.2.5.
By End User
8.3.3.2.6.
By Treatment Type
8.3.4.
Japan CAR-T Cell Therapy Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Product Type
8.3.4.2.2.
By Tumor Type
8.3.4.2.3.
By Indication
8.3.4.2.4.
By Targeted Antigen
8.3.4.2.5.
By End User
8.3.4.2.6.
By Treatment Type
8.3.5.
Australia CAR-T Cell Therapy Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Product Type
8.3.5.2.2.
By Tumor Type
8.3.5.2.3.
By Indication
8.3.5.2.4.
By Targeted Antigen
8.3.5.2.5.
By End User
8.3.5.2.6.
By Treatment Type
9. South
America CAR-T Cell Therapy Market Outlook
9.1.
Market Size & Forecast
9.1.1.
By Value
9.2.
Market Share & Forecast
9.2.1. By
Product Type
9.2.2.
By Tumor Type
9.2.3.
By Indication
9.2.4.
By Targeted Antigen
9.2.5.
By End User
9.2.6.
By Treatment Type
9.2.7.
By Country
9.3.
South America: Country Analysis
9.3.1.
Brazil CAR-T Cell Therapy Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Product Type
9.3.1.2.2.
By Tumor Type
9.3.1.2.3.
By Indication
9.3.1.2.4.
By Targeted Antigen
9.3.1.2.5.
By End User
9.3.1.2.6.
By Treatment Type
9.3.2.
Argentina CAR-T Cell Therapy Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Product Type
9.3.2.2.2.
By Tumor Type
9.3.2.2.3.
By Indication
9.3.2.2.4.
By Targeted Antigen
9.3.2.2.5.
By End User
9.3.2.2.6.
By Treatment Type
9.3.3.
Colombia CAR-T Cell Therapy Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Product Type
9.3.3.2.2.
By Tumor Type
9.3.3.2.3.
By Indication
9.3.3.2.4.
By Targeted Antigen
9.3.3.2.5.
By End User
9.3.3.2.6.
By Treatment Type
10. Middle
East and Africa CAR-T Cell Therapy Market Outlook
10.1.
Market Size & Forecast
10.1.1.
By Value
10.2.
Market Share & Forecast
10.2.1. By
Product Type
10.2.2.
By Tumor Type
10.2.3.
By Indication
10.2.4.
By Targeted Antigen
10.2.5.
By End User
10.2.6.
By Treatment Type
10.2.7.
By Country
10.3.
MEA: Country Analysis
10.3.1.
South Africa CAR-T Cell Therapy Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Product Type
10.3.1.2.2.
By Tumor Type
10.3.1.2.3.
By Indication
10.3.1.2.4.
By Targeted Antigen
10.3.1.2.5.
By End User
10.3.1.2.6.
By Treatment Type
10.3.2.
Saudi Arabia CAR-T Cell Therapy Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Product Type
10.3.2.2.2.
By Tumor Type
10.3.2.2.3.
By Indication
10.3.2.2.4.
By Targeted Antigen
10.3.2.2.5.
By End User
10.3.2.2.6.
By Treatment Type
10.3.3.
UAE CAR-T Cell Therapy Market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Product Type
10.3.3.2.2.
By Tumor Type
10.3.3.2.3.
By Indication
10.3.3.2.4.
By Targeted Antigen
10.3.3.2.5.
By End User
10.3.3.2.6.
By Treatment Type
11.
Market Dynamics
11.1.
Drivers
11.2.
Challenges
12.
Market Trends & Developments
12.1.
Merger & Acquisition (If Any)
12.2.
Product Launches (If Any)
12.3.
Recent Developments
13.
Porters Five Forces Analysis
13.1.
Competition in the Industry
13.2.
Potential of New Entrants
13.3.
Power of Suppliers
13.4.
Power of Customers
13.5.
Threat of Substitute Products
14.
Competitive Landscape
14.1.
Gilead Sciences, Inc.
14.1.1. Business
Overview
14.1.2. Company
Snapshot
14.1.3. Products
& Services
14.1.4. Financials
(As Reported)
14.1.5. Recent
Developments
14.1.6. Key
Personnel Details
14.1.7. SWOT
Analysis
14.2.
Novartis AG
14.3.
Bristol-Myers Squibb Company
14.4.
AbbVie Inc.
14.5.
Cellectis SA
14.6.
Amgen Inc.
14.7.
Pfizer Inc
14.8.
Merck KgaA
14.9.
Intellia Therapeutics, Inc.
14.10.
Johnson & Johnson
15.
Strategic Recommendations
16.
About Us & Disclaimer